Skip to main content
Evidence Snapshot

Protein kinase C eta type

CHEMBL3616 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:06:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3616
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C eta type as ChEMBL target CHEMBL3616, mapped to UniProt P24723. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C eta type
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3616
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P24723
Protein kinase C eta type
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Protein kinase C eta type matters

As of 2026-09-14

Protein kinase C eta type is reviewed as Protein kinase C eta type (UniProt P24723); the current evidence base includes 1 approved drug, 1240 compounds, and 326 assays, with lead potency reaching pChEMBL 10.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 1240 compounds, and 326 assays for this target. The dominant activity type is IC50. CHEMBL2148106 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL2148106 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Protein kinase C eta type matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P24723, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1240
Total Compounds
326
Total Assays
1
Approved Drugs
IC50: 291.0, KI: 54.0, KD: 131.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2148106
 10.0 Ki —
No preferred name
CHEMBL2418196
 9.7 Ki —
No preferred name
CHEMBL388978
 9.6 IC50 —
No preferred name
CHEMBL399981
 9.5 Ki —
No preferred name
CHEMBL265998
 9.5 Ki —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:06:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3616